A trial of a DNA vaccine in low grade B cell follicular lymphoma (LIFTT)

Cancer type:

Blood cancers

Low grade lymphoma

Lymphoma

Non-Hodgkin lymphoma

Status:

Results

Phase:

Phase 1/2

This trial was looking at a DNA vaccine Open a glossary item for a type of low grade non Hodgkin lymphoma (NHL) called follicular lymphoma. This trial was supported by Cancer Research UK.

Low grade NHL usually responds well to treatment and can be kept under control for years. But it is not usually completely cured.

Researchers want to find out if cancer vaccines might help to treat NHL. This trial was very early research into having a DNA vaccine. The aims of the trial were to

See if the immune system responded to the vaccine
Find the best dose of the vaccine
Learn more about the side effects

Summary of results

The trial team found that people with follicular lymphoma can have an immune response Open a glossary item to the vaccine.

The trial recruited 25 people. The first 5 people who took part had the lowest dose of the vaccine. As they didn’t have any serious effects, the next 5 patients had a higher dose. And so on, until the trial team found the best dose to give. This is called a ‘dose escalation study Open a glossary item ’.

Ten people had a mild reaction at the injection site, but nobody had any serious side effects at any dose in this study. Nearly three quarters of the people taking part had an immune response to the vaccine.

We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (peer reviewed Open a glossary item ) or published in a medical journal yet. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.